Pictet Asset Management Sa Hutchmed (China) LTD Transaction History

Pictet Asset Management Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$7.65 - $15.51 $638,010 - $1.29 Million	-83,400 Reduced 85.89%	13,700 $202,000
Q3 2022 Nov 14, 2022	SELL	$8.63 - $15.52 $4,315 - $7,760	-500 Reduced 0.51%	97,100 $860,000
Q2 2022 Aug 09, 2022	SELL	$8.59 - $20.77 $91,913 - $222,239	-10,700 Reduced 9.88%	97,600 $1.23 Million
Q1 2022 May 13, 2022	SELL	$15.52 - $35.65 $27,936 - $64,170	-1,800 Reduced 1.63%	108,300 $2.05 Million
Q4 2021 Feb 10, 2022	SELL	$28.89 - $35.33 $153,117 - $187,249	-5,300 Reduced 4.59%	110,100 $3.86 Million
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $4.12 Million - $4.96 Million	115,400 New	115,400 $843,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet Asset Management Sa with notifications on news.